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Abstract
Background: Genomic instability is a feature of multiple myeloma (MM), and impairment in DNA damaging
response (DDR) has an established role in disease pathobiology. Indeed, a deregulation of DNA repair pathways
may contribute to genomic instability, to the establishment of drug resistance to genotoxic agents, and to the
escape from immune surveillance. On these bases, we evaluated the role of different DDR pathways in MM and
investigated, for the first time, the direct and immune-mediated anti-MM activity of the nucleotide excision repair
(NER)-dependent agent trabectedin.
Methods: Gene-expression profiling (GEP) was carried out with HTA2.0 Affymetrix array. Evaluation of apoptosis, cell
cycle, and changes in cytokine production and release have been performed in 2D and 3D Matrigel-spheroid
models through flow cytometry on MM cell lines and patients-derived primary MM cells exposed to increasing
nanomolar concentrations of trabectedin. DNA-damage response has been evaluated through Western blot,
immunofluorescence, and DNA fragmentation assay. Trabectedin-induced activation of NK has been assessed by
CD107a degranulation. miRNAs quantification has been done through RT-PCR.
Results: By comparing GEP meta-analysis of normal and MM plasma cells (PCs), we observed an enrichment in
DNA NER genes in poor prognosis MM. Trabectedin triggered apoptosis in primary MM cells and MM cell lines in
both 2D and 3D in vitro assays. Moreover, trabectedin induced DDR activation, cellular stress with ROS production,
and cell cycle arrest. Additionally, a significant reduction of MCP1 cytokine and VEGF-A in U266-monocytes co-
cultures was observed, confirming the impairment of MM-promoting milieu. Drug-induced cell stress in MM cells
led to upregulation of NK activating receptors ligands (i.e., NKG2D), which translated into increased NK activation
and degranulation. Mechanistically, this effect was linked to trabectedin-induced inhibition of NKG2D-ligands
negative regulators IRF4 and IKZF1, as well as to miR-17 family downregulation in MM cells.
Conclusions: Taken together, our findings indicate a pleiotropic activity of NER-targeting agent trabectedin, which
appears a promising candidate for novel anti-MM therapeutic strategies.
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Background
Multiple myeloma (MM) is still an incurable hematologic
malignancy characterized by clonal proliferation of malig-
nant plasma cells (PCs) within the bone marrow (BM).
Current MM therapy includes triple- or double-drug com-
bination, based on proteasome inhibitors (PIs) and/or
immune-modulatory drugs (IMiDs) plus dexamethasone,
with or without chemotherapeutic agents [1]. Autologous
stem cell transplant is reserved to selected patients as con-
solidation following induction treatment. However, despite
recent advancements that significantly improved clinical
outcome, patients invariably progress to drug resistance.
DNA repair mechanisms have a crucial role for the
maintenance of the genome integrity, and their activa-
tion is fine tuned to resolve specific DNA damages. Cur-
rently, at least seven DNA repair active systems have
been described in MM as protection from different
DNA lesions [2]. Specifically, base excision repair (BER),
nucleotide excision repair (NER), and mismatch repair
(MMR) pathways are involved in the repair of
single-strand DNA damages; homologous recombination
(HR), classical non-homologous end joining (c-NHEJ),
and alternative NHEJ (a-NHEJ) pathways are conversely
involved in double-strand breaks (DSBs), while Fanconi
anemia pathway (together with NER and HR) is involved
in the repair of interstrand crosslinks [2, 3]. Dysregula-
tion of these systems has been found to promote tumor
progression, cell survival, and development of drug re-
sistance [2–4]. Furthermore, activation of DNA damage
response (DDR) has been involved in the upregulation
of ligands for activating receptors of natural killer (NK)
lymphocytes. Indeed, besides participating in cell cycle
control and induction of apoptosis, DDR works as a sen-
sor for cellular stress or transformation, inducing recog-
nition by the immune system [5, 6].
Genomic instability is a major hallmark of MM and
most of the drugs currently used in the treatment of
MM have direct genotoxic activity (i.e., melphalan,
doxorubicin, cyclophosphamide) or interfere with the
DNA repair machinery (PIs or IMiDs) [2]. Accordingly,
these drugs have been reported to trigger the expression
of DNAM-1 and NKG2D ligands on MM cells and to
induce NK cells activation [7, 8].
Herein, the expression and prognostic relevance of genes
of DNA repair pathways in MM has been investigated.
Since overexpression of NER pathway has been found,
evaluation of the direct and immune-mediated anti-MM
activity of the NER-targeting agent trabectedin in 2D and
3D experimental models of MM has been performed.
Methods
Cell lines, MM primary cells, and drugs
Multiple myeloma cell lines were cultured at 37 °C with
5% CO2. AMO-1, U266, and NCI-H929, SKMM1 were
purchased from DSMZ (Braunschweig, Germany).
AMO-BZB and AMO-CFZ were kindly provided by Dr.
Christoph Driessen (Eberhand Karls University,
Tübingen Germany), MM1S and RPMI-8226 were pur-
chased from ATCC (Manassas, VA, USA), and OPM2
and RPMI-8226 DOX40 were kindly provided by Dr.
K.C. Anderson (Dana-Farber Cancer Institute, Harvard
Medical School, Boston, MA, USA). All these cells were
cultured in RPMI-1640 medium (Gibco, Life Technolo-
gies) supplemented with 10% heat-inactivated fetal
bovine serum (FBS) and 100 U/mL penicillin, and
100 μg/mL streptomycin (GIBCO; Thermo Fischer,
Carlsbad, CA). U266 and U266 LR7 (kindly provided by
Dr. A. Pandiella, Instituto de Biología Molecular y
Celular del Cáncer, CSIC-Universidad de Salamanca,
Salamanca, Spain) were cultured in RPMI-1640 with
20% FBS and 100 U/mL penicillin, and 100 μg/mL
streptomycin. JJN3 were purchased from DSMZ and
were cultured in Dulbecco’s modified Eagle medium
supplemented with 20% FBS and 100 U/mL penicillin,
and 100 μg/mL streptomycin.
NK-92 CI were obtained from NantKwest (Dr. Kerry
S. Campbell) and cultured in alpha-MEM medium with
ribonucleosides and deoxyribonucleosides (Gibco,
Thermo Scientific) supplemented with 10% horse serum,
10% FBS, 0.2 mM myo-inositol (Sigma), 2 mM L-glutam-
ine, 0.1 mM β-mercaptoethanol (Sigma), 0.002 mM folic
acid (Fisher Scientific), 1x NEAA (Gibco, Thermo Scien-
tific), 1 mM Na pyruvate (Gibco, Thermo Scientific),
100 U/mL penicillin, and 100 μg/mL streptomycin (Life
Technologies) and 100 IU/mL of recombinant human
IL-2 (IL-2 improved sequence, Miltenyi).
Primary MM cells were immune-magnetically sorted
by using CD138 MicroBeads (MACS, Miltenyi, accord-
ing to producers’ guidelines) from leftover samples of
three MM patients’ bone marrow aspirates after all
diagnostic procedures. All patients had provided the in-
formed consent according to institutional bioethical
standards, and all the samples have been anonymized
before use (institutional approval n. 120/2015, within
the project Innovative immunotherapeutic treatments
of human cancer, MultiUnit—Multi Unit Regional
n.16695).
Human monocytes were obtained by immune magne-
tical separation from healthy donor peripheral blood
mononuclear cells (PBMCs) after Ficoll-Paque
density-gradient separation. Specifically, BD IMag™
anti-human CD14 magnetic particles were used for
positive selection of CD14+ monocytes according to
producers’ guidelines.
Ascorbic acid, as antioxidant agent, was purchased
from Sigma-Aldrich (Saint Louis, USA).
Trabectedin (PharmaMar, Madrid, Spain) was recon-
stituted in DMSO.
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Virus generation and transduction of MM cells
MM cells stably expressing miR-17-92 cluster have been
gently provided by Dr. E. Morelli. These cells have been
obtained by using a PMIRH17-92PA-1 lenti-vector
(System Biosciences, Palo Alto, CA, USA) through a
methodology already described elsewhere [9, 10]. Briefly,
packaging of the miR-17-92 cluster constructs in pseu-
doviral particles was performed in 293Ta cells using the
Lenti-Pac FIV Expression Packaging Kit (FPKLvTR-20),
according to the manufacturer’s instructions (Geneco-
poeia, Rockville, MD, USA). After transfection of 293 T
cells, supernatants containing miR-17-92 lentivirus were
collected at 8-h intervals, filtered, and used for two
rounds of transduction of U266 cells (1 × 106) in the
presence of 8 mg/mL of polybrene (Sigma-Aldrich). Two
days after transduction, selection with 1 μg/ml puro-
mycin for 3 days was performed to achieve almost 100%
transduced cells. Empty lentivirus transduced cells were
used as a control for the experiments.
Apoptosis evaluation
MM cells (2 × 105) were treated with dose escalation of
trabectedin (0-0.1-0.25-0.5-1-2.5 nM) and analyzed for
apoptosis after 24, 48, and 72 h through Annexin V/
7-AAD flow cytometry assay (Becton Dickinson). All
experiments have been performed at least three times.
Primary MM cells were exposed to 2.5 nM of Trabec-
tedin and apoptosis was evaluated after 24 h.
Apoptosis was further investigated at molecular level,
analyzing the cleaved/total levels of caspase 3 and
PARP by Western blot.
Cell cycle analysis
U266 and MM1S (1X106) were cultured in the presence
of trabectedin (1 nM and 0.1 nM, respectively) in
6-wells plate for 48 h. Cells were then collected and
washed twice with PBS 1X. Subsequently, 1 mL of 70%
ice cold ethanol for each sample was added. Cells were
stored at − 20 °C until used and then centrifuged and
washed twice with PBS 1X. Cells were then resuspended
in 1 mL of PI staining solution (100 μg/mL of ribonucle-
ase A, 50 μg/mL of propidium iodide, and 0.01% of
NP-40) and incubated for 1 h at room temperature, in
the dark. Analysis was performed with flow cytometer
and repeated three times.
3D model
We established a 3D in vitro model of MM cell lines alone
or in the presence of human monocytes using Matrigel®
matrix (Corning). Briefly, 1 × 105 MM cells (U266, OPM2,
MM1S) alone or in co-culture with 0.5 × 105 CD14+
monocytes (2:1 MM/monocytes ratio) were resuspended
in ice-cold matrigel and a matrigel drop of 35 μL was
placed in 24-wells plate coated with a sterile parafilm dish
to form a Matrigel-spheroid. After 30 min of incubation at
37 °C, 500 μL of medium with different concentrations of
trabectedin was added to each well and the spheroids were
incubated for 72 h. Matrigel-spheroids were then resus-
pended in Dispase (Sigma-Aldrich) and the recovered cells
were stained with annexin-V/ 7AAD for analyzing apop-
tosis induction by flow-cytometry. Supernatants were col-
lected to analyze cytokines expression. Alternatively,
Matrigel-spheroids were stored for immunohistochemistry
evaluation. All experiments have been performed at least
three times.
Immunohistochemistry
Matrigel-spheroids of either tumor cells alone or
co-cultured with CD14+ monocytes isolated from healthy
donors were fixed in 0.3% glutaraldehyde, then in 4.21%
formaldehyde, and subsequently paraffin-embedded. Serial
section of 4-μm-thick were cut and mounted on
acid-cleaned glass slides, which were dewaxed with xylene,
and processed for hematoxylin-eosin staining and
immunohistochemistry.
Slides were incubated overnight at 4 °C with
anti-g-H2ax monoclonal antibody (Cell Signaling) and
anti-cleaved caspase 3 (Santa Cruz Technologies) primary
antibodies, washed with PBS three times and incubated
with appropriate chromogen-conjugated secondary anti-
body for 1 h at room temperature. After washings using
PBS, samples were observed by an optical microscope and
images were acquired.
Single-cell gel electrophoresis (Comet) assay
Comet assay (Trevigen) was performed according to
manufacturer’s instructions. Briefly, cells were harvested
(1 × 105 cells per pellet), mixed with 200 mL
low-melting agarose, and layered onto agarose-coated
glass slides. The slides were immersed in lysis solution,
and then placed into a horizontal electrophoresis appar-
atus filled with fresh alkaline or neutral electrophoresis
buffer. After electrophoresis (30 min at 1 V/cm tank
length), air-dried and neutralized slides were stained with
Dapi and kept in a moist chamber in the dark at 4 °C. Im-
ages were acquired at × 63 oil immersion with an SP2
Leica Zeiss confocal laser-scanning microscope.
Mitochondrial membrane potential and ROS/superoxide
analysis
MM cells (5 × 105) were seeded in 12-wells plate and
were incubated for 24 h, untreated or treated with
sub-lethal doses of trabectedin (depending on cell line),
in the presence or absence of ascorbic acid (25 μM), as
antioxidant agent. Trabectedin-induced changes in the
production of mitochondrial membrane potential
(MMP) and radical oxygen species (ROS) were evaluated
by MitoScreen assay (Becton Dickinson) and Total ROS/
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Superoxides Detection kit (ENZO Life Sciences) respect-
ively, by flow cytometry according to producer’s
guidelines.
Flow cytometry and degranulation assay
The expression of the NKG2D and DNAM-1 ligands on
different MM cells was evaluated, after 48 h of culture in
the presence of trabectedin, by using
fluorochrome-conjugated antibodies against MIC-A/B
(Becton Dickinson), ULBP 1 (R&D Systems), ULBP 2-5-6
(R&D Systems), PVR (R&D Systems), and NECTIN-2
(Becton Dickinson) according to producer’s guidelines.
NK cell degranulation was evaluated using the
CD107a staining. Specifically, trabectedin-treated MM
cell lines were washed twice in complete medium and
incubated with NK-92 CI cell line at effector/target (E:T)
ratio of 1:1, in a U-bottom 96-well plate in complete
medium at 37 °C and 5% CO2 in the presence of
anti-CD107a/PE (Becton Dickinson) for 2 h. Cells were
then stained with anti-CD3/PcP and anti-CD56/APC to
identify NK cell population. NK cells positive for
CD107a were considered as degranulating/activated cells
able to induce cytotoxicity.
All experiments were acquired by an ATTUNE Nxt
(Thermo Scientific) flow cytometer. For each sample, at
least 1 × 104 events in the gate of interest were acquired.
RNA extraction and quantitative real-time-PCR
Total RNA from MM cells was prepared with TRIzol®
Reagent (Life Technologies) according to manufacturer’s
instructions. The integrity and quantity of total RNA
was assessed using the NanoDrop Spectrophotometer
(Thermo Scientific). The single-tube TaqMan miRNA
assay (Life Technologies) was used to detect and quan-
tify mature miR-17, miR-18a, miR-19a, miR-19b,
miR-20a, miR-92a, performing a real-time polymerase
chain reaction (RT-PCR) using TaqMan®Fast Universal
PCR Master Mix on a ViiA7 RT reader (Life Technolo-
gies). MiRNAs expression was normalized on the
RNU44 snoRNA (Life Technologies). Comparative RT–
PCR was performed in triplicate, including no-template
controls. Relative expression was calculated by using the
ΔΔ-cycle threshold (CT) method [11].
Gene-expression profiling
U226 MM cells (3 × 106), obtained from two different
experiments, were treated with PBS or 2.5 μM of trabec-
tedin for 24 h. Gene expression profiling was performed
as described elsewhere [12]. Briefly, total RNA (tRNA)
was extracted through column purification with RNeasy
kit (Qiagen, Hilden, Germany). A total of 300 ng RNA
was used as starting material for preparing the
hybridization target by using the Ambion® WT Expres-
sion Kit (Ambion, Life Technologies). The integrity,
quality, and quantity of tRNA were assessed by the
Agilent Bioanalyzer 2100 (Agilent Technologies, Santa
Clara, CA) and NanoDrop 1000 Spectrophotometer
(Thermo Scientific, Wilmington, DE). The amplification
of cRNA, the cleanup, and the fragmentation were per-
formed according to the Affymetrix’s procedures. Micro-
array data were generated by Human transcriptom array
2.0 ST (Affymetrix Inc., Santa Clara, Ca). Arrays were
scanned with an Affymetrix GeneChip Scanner 3000.
Raw data produced by the Affymetrix Platform (i.e., CEL
files) were processed and RMA normalized using
Affymetrix Expression Console (EC). Data set has been
deposited under the GEO accession number GSE128020.
Gene set enrichment analysis and gene ontology
We used the gene set enrichment analysis (GSEA) [13]
tool to enrich the target pathways with statistically sig-
nificant differences between trabectedin treated versus
untreated cells. Indeed, given a specific gene expression
profile sorted by the expression ratio between the two
conditions, the target pathway is considered significantly
enriched if members are enriched in the top (up-regu-
lated) or bottom (down-regulated) region of the profile.
GSEA software then calculates an enrichment score (ES)
by using a Kolmogorov-Smirnov test, to measure the de-
gree to which the pathway is enriched in the top-ranked
or bottom-ranked region of the profile. Next, ES is nor-
malized (NES) according to the number of genes belong-
ing to the pathways, in order to make comparable
pathways with different size. Of note, this process takes
into account the contribution of all genes included into
the analysis, including those with minimum fold change.
GSEA analysis parameters have been set as follows:
number of permutations: 1000; permutation type: gene_-
set; metric for ranking genes: log2 ratio of Classes; size
of genesets: 25–500 genes; gene sets evaluated: Hallmark
gene sets and C2 curated gene sets from MSigDB.
Additionally, genes upregulated or downregulated with
a fold change of at least 1.5 where analyzed with
ClueGO, a Cytoscape plug in app that visualizes
non-redundant biological terms for large clusters of gene
sets in a functionally grouped network [14, 15].
Western blot
Proteins were extracted from MM cells after lysing in
NP40 CellLysis Buffer (Novex) containing a cocktail of
protease and phosphatase inhibitors (Thermo Scientific,
Waltham, MA). Whole cells lysates (20–30 μg/well)
were loaded and separated on 4–12% NovexBis–Tris
SDS–acrylamide gels or 3–8% Tris-Acetate Protein Gels
(Gibco, Life Technologies). Proteins were then trans-
ferred on nitrocellulose membranes by Trans-Blot Turbo
Transfer Starter System (Bio-Rad, Berkeley, CA). Subse-
quently, membranes were blotted with the following
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primary antibodies: anti-P21, anti-BCL2, anti-RAD51,
anti-MCL1, anti-PRO-CASP3, anti-C-CASP3, anti-
CDK6, anti-cyclinD1, anti-E2F1, anti-IKZF1, anti-
XRCC1, anti-RPA32 (Cell Signaling) and anti-cPARP,
anti-PARP, anti-BCL2, anti-IRF4, anti-PTEN, anti-XPF,
anti-DDB2, anti-ERCC1, anti-actin, anti-vinculin, and
GAPDH (Santa Cruz). To study major signaling check-
points in response to active DNA damage, a specific
commercial kit from Cell Signaling (DNA Damage Anti-
body Sampler Kit #9947) has been used, as already de-
scribed in previous work by us and others [16–18]. The
kit includes the following primary antibodies: anti-phos-
pho (p)P53 (Ser15), anti-gammaH2AX (Ser139),
anti-pATM (Ser1981), anti-pATR (Ser428), anti-pCHEK1
(Ser345), anti-pCHEK2 (Thr68), and anti-pBRCA1
(Ser1524). All these forms are virtually absent in normal
conditions and are activated in response to DNA damage
to induce an attempt to DNA repair and block cell cycle
progression (through, for example, p21). GAPDH expres-
sion has been used as a protein loading control for this
kit. Blots were then incubated with goat anti-mouse or
goat anti-rabbit HRP-conjugated antibodies (Santa Cruz
Biotechnology); immunoreactive bands were detected by
use of enhanced chemiluminescence (ECL) method, ac-
quired through the C-DIGIT scanner (LI-COR) and quan-
tified by Image Studio Lite 5.0 (LI-COR).
Immunostaining for confocal microscopy
Trabectedin-treated and control MM cells were seeded
onto glass coverslips and cytospin for 5 min at 800 rpm
was performed. Cells were then washed in PBS, fixed in 4%
paraformaldehyde for 12 min, washed three times with
PBS, followed by permeabilization with 0.01% Triton-X for
15 min, and again washed in PBS containing 0.5% BSA.
Cells were then incubated with anti-g-H2ax monoclonal
antibody (cell signaling) overnight at 4 °C, washed with PBS
three times, and incubated with Alexa-fluor 488-conjugated
secondary antibody (Molecular Probes, Life Technologies,
NY) for 1 h at room temperature. Glass coverslips were
then washed three times with PBS and mounted with
Vecta-Shield mounting media containing DAPI. Samples
were visualized and images captured using a Leica micro-
scope. Images were acquired at × 63 oil immersion with an
SP2 Leica Zeiss confocal laser-scanning microscope.
Cytokines analysis
A panel of different cytokines including IL1b, IL4, IL6, IL8,
IL23, TNF, IFNg, G-CSF, IP10, MCP1, IL10, and VEGF were
detected in the supernatants of CD14+ cells alone obtained
by PBMCs of healthy donors and co-cultured with MM cells
in 3D Matrigel-spheroids, in the presence or absence of
Trabectedin, using BD CBA Human Soluble Protein Flex
Set system (Becton Dickinson, Heidelberg, Germany).
Samples from three different experiments were analyzed
with an Attune Nxt Thermo Scientific flow cytometer.
Tube assay formation
A drop of 50 μL of Matrigel (CORNING) were used to
coat 96-wells plates and allowed to polymerize at 37 °C
for 30 min. Then, 15 × 103 HUVECs were seeded in each
well and then 50 μL of conditioned medium from
trabectedin-treated cells were added. After 1-h incuba-
tion at 37 °C, at least pictures of three representative
fields per well were taken using phase contrast micros-
copy. The tubulogenic potential was quantified by esti-
mating the total tube length and the number of nodal
branchpoints (a single pixel connected to three or more
pixels), through the “Pipeline 1.4” tool [19] (https://sour
ceforge.net/projects/pipelinetfaanalysis/). All experi-
ments have been performed at least three times.
Gene expression datasets analysis
Datasets of gene expression profiling of MM were re-
trieved from GEO database (Table 1) or from the MMRF
Table 1 Datasets of gene expression profiling of MM retrieved from GEO database
Database GEO Platform Institute Organism Summary
1 GSE47552 Affymetrix Human





Homo sapiens Analysis of plasma cells from patients with monoclonal
gammopathy of undetermined significance (MGUS) (n = 20),
smoldering multiple myeloma (sMM) (n = 33), symptomatic
MM (n = 41), and healthy donors (n = 5).
2 GSE39754 Affymetrix Human
Exon 1.0ST
Array(GPL5175)
Dana-Farber Cancer Institute Homo sapiens Gene expression microarray datasets from CD138 purified
plasma cells isolated from 170 patients with newly diagnosed
MM and 6 healthy subjects. All patients received triple drug
regime—Vincristine, Adriamycin, and Dexamethasone
(VAD)—as induction therapy followed by autologous stem
cell transplant (ASCT) as a maintenance therapy.
3 GSE6477 Affymetrix Human
Genome U133A
Array (GPL96)
Mayo Clinic Homo sapiens Gene expression profile of CD138 purified plasma cells from
22 MGUS, 24 sMM, 69 newly diagnosed MM, 32 relapsed MM,
and 15 healthy subjects. Each sample has been further
characterized by FISH for the identification of hyperdiploidy.







Homo sapiens This series of microarray experiments contains the gene
expression profiles of immunomagnetically purified CD138+
plasma cells obtained from 5 normal donors, 11 MGUS, 133
MM, and 9 plasma cell leukemia at diagnosis
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researcher gateway portal (https://research.themmrf.org).
The GSE47552 dataset includes data from 5 healthy do-
nors (HD), 20 patients with MGUS, 33 high-risk sMM,
and 41 MM; the GSE39754 includes results from 6 HD
and 170 MM; the GSE6477 includes gene expression
profiles of 22 MGUS, 24 sMM, 69 newly diagnosed MM,
32 relapsed MM, and 15 healthy subjects; and the
GSE13591 dataset contains the gene expression profiles
of immunomagnetically purified CD138+ plasma cells
obtained from 5 HD, 11 MGUS, 133 MM, and 9 plasma
cell leukemia at diagnosis.
The CoMMpass (Relating Clinical Outcomes in MM
to Personal Assessment of Genetic Profile) Trial
(NCT0145429), a longitudinal study in MM, relating
clinical outcomes to genomic and immune-phenotypic
profiles of CD138+ selected plasma cells from the BM of
newly diagnosed MM patients (in the release used in this
work (interim analysis 8, IA8), RNA-seq, together with
clinical data, was available for 549 MM patients).
Datasets including MM cell lines gene expression pro-
filing were retrieved from GEO database with the acces-
sion code GSE68379 and GSE6205. These data were
normalized in Transcription analysis console (TAC,
Thermo Scientific) software and result table processed
through R Studio (R version: 3.5).
Statistical analysis
Differences between means were analyzed by using
GraphPad statistical package. The results were expressed
as the mean ± SD of at least three different experiments,
and the significance assessed by the two-tailed Student t
test or Mann-Whitney test according to samples distribu-
tion. A p value of 0.05 or less was considered statistically
significant. Overall survival (OS) and progression-free sur-
vival (PFS) analyses (Kaplan-Meier curves and log-rank
test) have been performed by using SPSS statistical soft-
ware on data retrieved by the CoMMpass database.
Results
NER genes are highly expressed in MM patients and
correlate with prognosis
To establish the role of known DNA repair pathways in
MM, a meta-analysis of all available gene expression pro-
filing (GEP) data sets was performed by comparing the ex-
pression levels of genes belonging to each pathway (BER,
NER, MMR, HR, c-NHEJ, a-NHEJ, FA) in primary cells
from MM patients with normal PCs from healthy donors
(gene lists are reported in Additional file 1: Table S1). As
shown in Fig. 1a and Additional file 2: Figure S1A, upreg-
ulation of genes belonging to NER in MM cells, as com-
pared to normal PCs, was found. Specifically, 7 out of 31
genes involved in the NER system were significantly
deregulated in 4/5 datasets analyzed. Conversely, only 3/
18, 0/10, 0/27, 0/15, 1/9, and 0/16 genes were deregulated
in BER, MMR, HR, C-NHEJ, A-NHEJ, or FA respectively.
Next, NER-associated genes were evaluated for their im-
pact on MM patient prognosis by analyzing data from
CoMMpass Trial (NCT0145429). To this aim, a multivari-
ate COX regression analysis, including all NER-associated
genes (31) and the 4 R-ISS variables, i.e., B2-microglobulin,
albumin, LDH, and adverse cytogenetic [20] was per-
formed. Four genes only (XPA, RAD23B, XAB2, and
POLD3) showed independent predictive power (Fig. 1b
left panel). Among them, a higher expression of RAD23B,
XAB2, and POLD3 was associated with poor prognosis,
whereas a higher expression of XPA was associated with
better survival. Since Cox-regression model reported a
similar relative contribution (positive or negative) for each
variable, a score to each gene (low expression = 1, mid ex-
pression = 2, and high expression = 3) was assigned and
then a prognostic risk score (RS) was built as follows:
RAD23B + XAB2 + POLD3 − XPA. According to the me-
dian RS, patients were divided into NER “low” and “high”
risk groups (Fig. 1b right panel). The prognostic model
strongly associated with survival, with patients in low-risk
group experiencing a significant hazard ratio reduction of
about 70% (Fig. 1b right panel). Interestingly, the same
analysis in all other DNA repair systems (Additional file 2:
Figure S1B) did not reached results with the predictive
value or NER-based score.
The finding that upregulation of different NER genes
in MM PCs was correlated to poor prognosis suggested
a major role for NER in MM pathobiology. On this
basis, the efficacy of NER-targeting agents in this setting
was investigated. Therefore, the anti-MM activity of tra-
bectedin (Ecteinascidin 743), whose mechanism of ac-
tion relies on NER system expression [21], was studied.
Specifically, this drug binds to the minor groove of DNA
and traps the NER machinery as it attempts to repair
DNA, leading to the generation of lethal DNA double
strand breaks. To our knowledge, the antitumor activity
of trabectedin in MM has not been described so far.
Trabectedin exerts potent anti-MM activity in vitro and in
3D models
The activity of trabectedin against MM cells was next in-
vestigated. Firstly, a panel of 12 MM cell lines, including
several drug-resistant derived cells, was evaluated for
sensitivity to increasing doses of trabectedin. Overall, all
MM cell lines (except for LR7) were very sensitive to
trabectedin exposure, with significant IC50 values for
apoptosis at 72 h ranging from 0.5 to 2.5 nM (Fig. 2a).
Moreover, the anti-MM activity of trabectedin was con-
firmed on primary cells from three different relapsed
MM patients, by exposing cells to 2.5 nM of the drug.
Importantly, also in this setting, over a significant 50%
increase in apoptosis after 24 h (Fig. 2b and
Additional file 3: Figure S2A) was observed (p: 0.02).
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Interestingly, we observed a dichotomic pattern of re-
sponse after 24 h of treatment with trabectedin among
all cell lines evaluated. Specifically, as reported in Fig. 2a,
more than 50% of cells belonging to RPMI8226, DOX40,
JJN3, H929, MM1S, and AMO-BZB cell lines were dead
with 2.5 nM of trabectedin. We called these cells “quick
responders,” and, as shown in Fig. 2c, by investigating
the expression of several proteins belonging to the NER
system, we observed that they expressed a significant
higher protein level of ERCC1 as compared to “slow re-
sponders.” Indeed, the complex ERCC1/XPF is necessary
for the formation of the trabectedin-induced DNA-DSB
and ERCC1 expression has already been associated with
response to trabectedin in cancer patients [22, 23]. As
showed in Additional file 3: Figure S2B, none of the
other evaluated proteins (XRCC1, DDB2, RPA32) exhib-
ited a pattern associated with response to trabectedin.
Along the same line, we investigated the expression of
genes belonging to the NER pathway by interrogating
two different publicly available datasets (GSE68379 and
GSE6205) including several of the cell lines we used in
our experiments [24, 25]. Unfortunately, while in both
datasets, cells segregate in an unsupervised hierarchical
clustering accordingly to their response to trabectedin
(quick vs slow responders, Additional file 3: Figure S2C),
we were unable to find significantly deregulated genes (a
trend was observed for DDB1, CETN2, and POLD4; data
not shown).
To strengthen our findings, trabectedin was further
studied by a new relevant 3D model in which MM cells
grow in matrigel-based spheroids. In this model, U266
cells form multicellular niches recapitulating the bone
marrow structure of MM patients. The addition of tra-
bectedin to Matrigel-spheroids impaired the develop-
ment of MM niches (Fig. 2d upper panel). The 3D
architecture mimics the protective effect of BM tissue
structure on MM cells from drug-induced cytotoxicity
and, indeed, a slight reduction of trabectedin activity in
A
B
Fig. 1 NER genes upregulation in MM cells and its prognostic correlation. a Meta-analysis of four different GEP datasets of MM comparing the
expression levels of genes belonging to NER DNA-repair pathway in PCs from MM patients with PCs from healthy donors. b Shows a forest plot
(on the left) reporting the results of the multivariate COX regression analysis performed on all NER-associated genes and on the 4 prognostic
factors included in the R-ISS (B2-microglobulin, albumin, LDH, and adverse cytogenetic). A Kaplan-Meier curve (on the right) reports the results of
the prognostic model built by dividing patients into NER “low” and “high” risk groups according to the previously selected genes expression.
Importantly, patients in low-risk group experienced a significant hazard ratio reduction of about 70%





Fig. 2 (See legend on next page.)
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this model, as compared to 2D classic cultures of several
MM cell lines (U266, Fig. 2d; MM1S and OPM2,
Additional file 3: Figure S2D), was observed. However,
this model does not fully recapitulate the BM micro-
environment (BMM). To overcome this limitation, tak-
ing into account that macrophages infiltrate the BMM
and protect MM cells from DNA-damaging [26, 27],
Matrigel-spheroids in which MM cell lines (U266,
MM1S, and OPM2) were co-cultured with healthy
donors-derived monocytes were generated. As expected,
after 72 h, monocytes/macrophages greatly improved the
proliferative activity and viability of MM cells, and
strongly promoted the generation of multi-cellular “mi-
croenvironmental” niches. Nevertheless, trabectedin
overcame monocyte-dependent protective effects and
significantly induced apoptosis in all MM cell lines
tested (U266, MM1S, and OPM2) (Fig. 2d lower panel
and Additional file 3: Figure S2D).
Trabectedin modulates the transcriptome and induces cell
cycle arrest, cellular stress, and DNA damage in MM cells
To shed light on molecular mechanisms underlying the
anti-MM activity of trabectedin, modifications in the gene
expression profile of U266 cells, untreated or treated with
2.5 nM of trabectedin for 24 h (unsupervised hierarchical
clustering is reported in Additional file 3: Figure S2E),
were investigated by performing a GSEA [13]. By using
both “hallmark” and “c2 curated” GSEA gene-sets, UV re-
sponse/DDR and mitotic spindle formation (i.e., cell cycle
progression) gene-sets were the most significantly modu-
lated putative functions (Fig. 3a and Additional file 3:
Figure S2F). Then, by taking advantage of the “ClueGO”
and “CluePEDIA” apps in Cytoscape [14, 15], the main
putative clusters of functions modulated by genes upregu-
lated or downregulated by trabectedin were identified
(Fig. 3a and Additional file 4: Figure S3A). Specifically,
pathways associated with apoptosis, cell-cycle, DNA-dam-
age, and cellular stress were the most significantly modu-
lated. Additionally, among genes belonging to NER
signaling, trabectedin significantly increased the expres-
sion of DDB2 (FC: 1.57), XPC (FC: 1.34), PCNA (FC: 1.7),
and RPA2 (FC:1.45) (Additional file 4: Figure S3B; DDB2
upregulation in two cell lines was also confirmed by
Western blot).
We then performed an in vitro validation of these bio-
informatics findings.
It is well known that in other malignancies,
trabectedin-induced apoptosis may occur in a
P53-dependent or independent manner [28]. Accord-
ingly, in our experimental setting, an increase of markers
of late apoptosis, cleaved (c)-PARP and c-caspase3, in
both P53-WT MM1S and P53-mutated U266 cell lines
after 48 h treatment (Fig. 3b left panel) was observed. By
immunohistochemistry, an increase of c-caspase
3-positive U266 cells from our 3D model after trabecte-
din treatment (Fig. 3b right panel) was further con-
firmed. Moreover, in U266 cells, a stronger reduction in
the anti-apoptotic protein BCL-2 than in MM1S was de-
tected (Additional file 5: Figure S4A). This effect was
paralleled by a deepest alteration in mitochondrial mem-
brane polarization (Fig. 3c). Additionally, in both cell
lines, ROS and superoxide production significantly in-
creased, confirming the predicted activation of stress
response pathways (Fig. 3d and Additional file 5:
Figure S4B). Then, to investigate whether DNA dam-
age and apoptosis were correlated with ROS produc-
tion, both U266 and MM1S cell lines were co-treated
with trabectedin and ascorbic acid as antioxidant.
Notably, despite a significant reduction in ROS levels,
the antioxidant did not protect MM cells from
trabectedin-induced apoptosis and DNA damage, eval-
uated as H2AX protein phosphorylation (γ-H2AX)
(Fig. 3d), demonstrating both effects (DNA damage
and apoptosis) to be independent from ROS produc-
tion (representative dot plots of U266 and MM1S MM
cells reporting trabectedin activity in term of apoptosis
in presence or absence of trabectedin and/or ascorbic
acid, were showed in Additional file 5: Figure S4B).
Unfortunately, the exact mechanism of trabectedin-as-
sociated ROS production (already observed in other
cellular systems [29]) is currently not fully understood.
We may hypothesize that, at least in our settings, ROS
(See figure on previous page.)
Fig. 2 Activity of trabectedin in MM cells. a Representative dot plots of dose-dependent apoptosis increase in U266 and MM1S cells after dose
escalation of trabectedin evaluated with annexin-V/7aad assay. In the lower left panel are represented the results of trabectedin activity on 12
MM cell lines at different time points. Each point represents the average result of at least 3 replicates. All cell lines (except for LR7) were very
sensitive to trabectedin, with an IC50 at 72 h ranging from 0.5 to 2.5 Nm (%viable cells at the IC50 point significantly lower as compared with the
control point, p < 0.01 for all cell lines). b Trabectedin activity on primary MM cells derived from 3 different patients, exposed to 2.5 nM of the
drugs. After 24 h, we observed over 50% apoptosis evaluated with annexin-V/7aad assay. c Western blots reporting the expression of XPF and
ERCC1 proteins in all the cell lines evaluated for sensibility to trabectedin treatment. On the right, evaluation of differences in protein expression
after quantization, normalization and removal of outliers through ROUT test (Q = 1%). d A representative immunohistochemistry images of 3D
model of U266 MM cells (in the absence or presence of macrophages) growth in matrigel-based spheroids, demonstrating the reduction of
proliferation niches in trabectedin treated cells respect to control. The right dot plots showed the pro-apoptotic effects of trabectedin both in
presence and in absence of macrophages (representative experiment of three) and the respective histograms showing the mean of three
different experiments. *p < 0.05
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are produced as a consequence of DNA double-strand
breaks, DNA damage response activation, and mito-
chondrial membrane potential alteration.
Next, cell cycle alterations upon trabectedin were
evaluated. In line with bioinformatics analysis, a
trabectedin-dependent S-phase arrest with progressive
decrease of cells in G0/G1 phases was observed
(Fig. 3e left panel). The scenario depicted by these re-
sults was further empowered by an increase in the
expression of the cell-cycle inhibitor p21WAF1 in
MM1S, and by downregulation of Cyclin D1 and
CDK6 in U266 (Fig. 3e right panel).
Lastly, the DNA-damaging activity of trabectedin was
studied. As a surrogate marker of DSBs, the expression
of γ-H2AX, a variant of histone 2A that is phosphory-
lated in the presence of DNA DSBs, was evaluated. Spe-
cifically, H2AX has a key role in DNA repair machinery
and its phosphorylation represents the first step to re-
cruit DNA repair proteins [30]. Additionally, g-H2AX is
organized in foci that are associated to DNA fragmenta-
tion during apoptosis and DNA damage [31]. By
Western blot, a strong increase of phosphorylated
H2AX in the presence of trabectedin (results for U266





Fig. 3 Trabectedin affects many cellular pathways. a On the upper left panel, the enrichment plots show significant gene-sets identified using
GSEA software on U266 RNA. The green curve represents the enrichment score curve. On the right, the pie charts report different gene sets with
up- or downregulation involved in trabectedin activity. b Western blot data showing levels of pro-apoptotic proteins c-PARP and c-caspase 3 after
trabectedin treatment in U266 and MM1S cells. On the right, immunohistochemistry images showed brown foci of activated c-caspase 3 in
trabectedin-treated U266 3D model compared to control. c Dot plots demonstrated modifications in mitochondrial membrane potential in MM1S and
U266 cells trabectedin-treated respect to control. d Histograms representative of three independent experiments showed apoptosis induction and ROS
production, after trabectedin treatment in U266 and MM1S cells, in the presence or absence of ascorbic acid (25uM) as antioxidant. In the lowest part,
Western blots reporting the expression of gamma-H2AX in U266 and MM1S alone or in the presence of trabectedin and/or ascorbic acid. e On the left,
a representation of the four phases of cell cycle, in two MM cell line (blue chart for MM1S and orange for U266), untreated or exposed to trabectedin.
On the right, Western blot reported the expression of protein involved in cell cycle: p21 in MM1S and cyclin D1 and CDK4 in U266. f A representation
of Western blot of g-H2ax expression in U266 and MM1S cells, in the upper panel. In addition, in single-cell gel electrophoresis (Comet) assay DNA
strand breaks are identified through structures resembling comets, observed by fluorescence microscopy. The representative images showed the DNA
damage in U266 and MM1S cell lines treated with 2.5 and 0.1 nM of trabectedin, respectively. Western blot images showed different proteins involved
in DNA damage and belonging to DNA repair system. On the right top, immunofluorescence image showing green g-H2ax foci within MM1S and
U266 nuclei exposed to 0.1 nM and 2.5 nM of trabectedin, respectively. *p < 0.05
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OPM2 in Additional file 5: Figure S4C) was observed.
These findings were empowered by demonstration of
γ-H2AX foci within the nuclei of U266 and MM1S cells
by confocal microscopy and by immunohistochemistry
in the 3D model of MM (Fig. 3f and Additional file 5:
Figure S4D). Furthermore, DNA fragmentation by a
COMET assay demonstrated that trabectedin induces
DNA damage and loss of chromatin organization in both
U266 and MM1S (Fig. 3f ). Accordingly, in both cell
lines, trabectedin induced increased expression of pro-
teins involved in DDR, including pATM and pATR, their
downstream mediators pChk1 and pChk2, RAD51,
pBRCA1, and pP53 (the latter only in MM1S) (Fig. 3f ).
Trabectedin reduces MM-macrophages-induced
angiogenesis
Due to the relevant role played by trabectedin as a
microenvironment-modulating agent [32, 33], the con-
centration of a panel of cytokines/chemokines related
with inflammation, chemotaxis, and angiogenesis in the
supernatants of 3D-spheroids of monocytes-MM cells
co-cultures (U266) alone or exposed to trabectedin was
investigated. As shown in Fig. 4a, a significant reduction
of MCP1, VEGF-A, and IL-10 (and a trend to reduced
IL-8) in U266 and monocytes co-cultures was observed.
Then, it was investigated if those modulations have any
role in impairing MM-macrophages (M0)-induced
angiogenesis. To verify our hypothesis, early passage
HUVECs were cultured with conditioned medium
obtained from 3D Matrigel-spheroids of MM (U266,
OPM2, and MM1S) plus M0 in the presence or absence
of trabectedin, after 72 h of culture. After 1 h,
conditioned medium from untreated Matrigel-spheroids
induced capillary-like structures to a higher extent as
compared to the supernatant derived from trabectedin-
treated co-cultures, as demonstrated by the significantly
higher tube-like structure length and number of node
branch points. This latter finding suggests anti-angio-




Fig. 4 Trabectedin effects on angiogenesis. a Evaluation of cytokines production and secretion in the supernatant of 3D-spheroids of U266 and
monocytes co-cultures treated with 2.5 nM of trabectedin. b Representative image from tubulogenic assay performed with supernatants of
treated (2.5 nM of trabectedin) or untreated 3D-spheroids of U266-monocytes co-cultures. The image was analyzed through the “Pipeline 1.4”
tool. In blue are reported the segments of neo-vessels/tubes. The histograms below show the tubulogenic potential, quantified by estimating the
total tube length and the number of nodal branchpoints (a single pixel connected to 3 or more pixels), of the supernatant derived from 3D
Matrigel-spheroids including monocytes co-cultured with 3 different MM cell lines. *p < 0.05
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Trabectedin increases the expression of NKG2D ligands in
MM cells and induces NK activation
Since DNA damage and cell stress have been found to
increase NKG2D and DNAM-1 ligands expression on
cancer cells, the role of trabectedin in MM cells suscep-
tibility to NK-mediated cytotoxicity was investigated.
Firstly, GEP analysis of known ligands (MICA, MICB,
ULBP1-5, PVR, Nectin-2) of NK activating receptors
(NKG2D and DNAM-1) demonstrated a significant up-
regulation of MICA and MICB genes (Fig. 5a). We con-
firmed such changes at protein level in several MM cell
lines by flow cytometry: as shown in Additional file 5:
Figure S4E, the highest increase in MICA/B was found
in OPM2 cells. Additionally, trabectedin treatment sig-
nificantly upregulated ULBP1 expression in the majority
of cell lines analyzed (Fig. 5a and Additional file 5: Fig-
ure S4E). To functionally assess the relevance of these
modulations, a degranulation assay was performed by
measuring CD107a expression on natural killer cells
(NK-92 CI) co-cultured with MM cells (U266, MM1S,
OPM2, and RPMI8226) exposed to trabectedin. In line
with the entity of ligands upregulation, the strongest sig-
nificant degranulation on NK-92 cells co-cultured with
trabectedin-treated OPM2 was observed, followed by
RPMI8226 and U266 (Fig. 5b and Additional file 5: Fig-
ure S4F). Conversely, no NK activation was observed in
the presence of trabectedin-treated MM1S where the
NK ligands were not upregulated.
Trabectedin activity is dependent from perturbation of
transcription factors and microRNAs networks
To investigate the transcriptional mechanisms under-
lying trabectedin-induced MICA/B upregulation in MM
cells, we explored in our GEP analysis of U266 cells the
mRNA expression of known transcription factors in-





Fig. 5 Trabectedin effects on MM recognition by innate immune system effectors. a On the left, expression levels of all known ligands of NK
activating receptors derived from the results of the GEP of U266 treated with 2.5 nM of trabectedin. On the right, overlay histograms (scattered
plots) underlying the modulation in MICA/B and ULBP1 expression in OPM2, U266, and MM1S, after trabectedin treatment. b Representative dot
plot (of 3 different experiments) reporting the % of CD107a NK-92 after co-culture with different MM cells exposed to PBS or to 0.25 nM (MM1S),
1 nM (OPM-2), or 2.5 nM (U266) of trabectedin. c In the upper part, expression levels of negative or positive regulators of MICA/B derived from
the results of the GEP of U266 treated with 2.5 nM of trabectedin. In the lower part, Western blot data showing protein expression of the
previously identified MICA/B regulators: IKZF1, IRF4, and E2F1; the densitometric analysis of Western blot was performed on the triplicate blots for
IKZF1 and E2F1 in both cell lines. d Sequences of miRNA families predicted to target at the same time the 3′UTR regions of MICA, MICB, and E2F1
(all upregulated after trabectedin treatment). These miRNAs present AAGUGC that interact with UUCACG motif of 3′UTR regions of previously
reported genes. e Histograms reporting the expression of miR-17 and miR-20a in U266 and OPM2 cells untreated or exposed to 2.5 nM and 1 nM
of trabectedin, respectively. f Overlay histogram reporting MICA/B expression in EV-U266 and 17-92-U266 cells alone or after treatment with
2.5 nM of trabectedin. On the right, histograms reporting the MFI of MICA/B of three different replicates. g Histograms showing apoptosis levels
in EV-U266 as compared to 17-92-U266 after trabectedin treatment with 2.5 nM. h Cartoon representing the pleiotropic activity of trabectedin in
MM, including direct cytotoxicity of trabectedin on MM cells, immune-modification of cytotoxicity on MM cells, and reduction of
angiogenesis. *p < 0.05
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Among MICA/B-positive regulators, only E2F1 was sig-
nificantly upregulated, while, among negative regulators,
IRF4 and IKZF1 were downregulated in MM cell lines
treated with trabectedin as compared to control (Fig. 5c).
Additionally, we further observed a trabectedin-dependent
increase of the transcription of CRBN, CUL4, and DDB2
genes, all involved in the ubiquitination of IKZF1 protein
(Additional file 5: Figure S4G).
E2F1, IRF4, and IKZF1 modulations were confirmed at
protein level in U266 and OPM2 cell lines after 48-h ex-
posure to trabectedin (Fig. 5c). Interestingly, while statis-
tically significant, IKZF1 downregulation is far less
pronounced in OPM2 than in U266 cell line, while E2F1
upregulation is stronger in OPM2. This could reflect a
different weight of the two signaling in NKG2D ligands
upregulation.
Moreover, to explore the post-transcriptional mecha-
nisms correlated to trabectedin exposure in the regula-
tion of MICA/B expression, we sought to examine
whether trabectedin could regulate the expression of
miRNAs. Indeed, by targeting the 3′ untranslated region
(3′-UTR) of different mRNAs at the same time and,
consequently, modulating their translation into proteins,
miRNAs have a pivotal role in regulating almost all cel-
lular function, including immune response. Indeed, in-
creasing evidence reports on their capability of
modulating, among others, the susceptibility of tumor
cells to NK cell-mediated lysis [35–37]. On this basis,
the miRNA target prediction tool mirDIP (http://ophi
d.utoronto.ca/mirDIP) has been used to identify miR-
NAs predicted to target, at the same time, MICA, MICB,
and E2F1 mRNAs (which we previously demonstrated,
in our experiments, to be upregulated after trabectedin
treatment). As shown in Fig. 5d, all these miRNAs belong
to well-characterized families, namely miR-17, miR-302,
miR-372, and C19MC, all part of an oncogenic signaling
network characterized by the presence of an AAGUGC
sequence [38]. Interestingly, all these miRNAs modulate
DNA damage response and cell cycle progression.
Taking into account the prominent role of miR-17-92
cluster in MM [10, 39–41] and the already reported cap-
ability of miR-17 family to modulate the expression of
NKG2D ligands [42–44], the effects of trabectedin on
the expression levels of miR-17 and miR-20a (the two
miRNAs of the miR-17-92 cluster belonging to the
miR-17 family) has been evaluated. As described in
Fig. 5e and in Additional file 5: Figure S4H, trabectedin
exposure significantly downregulated pri-miR-17-92,
miR-17, and miR-20a in both U266 and OPM-2 cell
lines. Importantly, as a control for the selectivity of tra-
bectedin activity, two additional mature miRNAs of the
miR-17-92 cluster (miR-19b and miR-92a), but not be-
longing to the miR-17 family, were not modulated after
treatment (Additional file 5: Figure S4I).
Next, to assessed the role of these miRNAs in the
regulation of NKG2DL expression, U266 cells were len-
tivirally transduced to generate a pri-MiR-17-92 overex-
pressing MM cell line (17-92-U266) (Additional file 5:
Figure S4J, reports expression levels of mature miRNAs
after transduction). Interestingly, 17-92-U266 cells dem-
onstrated a lower (but not significantly) baseline expres-
sion of MICA/B respect to empty vector U266 cells
(EV-U266), which levels increased significantly less after
trabectedin treatment (Fig. 5f ). We further observed an
increased resistance to trabectedin-induced direct cyto-
toxicity in 17-92-U266 cells as compared to empty vec-
tor: as shown in Fig. 5g and in Additional file: Figure
S4K, 17-92-U266 cells were significantly more resistant
to trabectedin-induced apoptosis as compared to
EV-U266 cells. Overall, these findings indicate a role for
miR-17 family in trabectedin-dependent NKG2D ligands
upregulation in MM cells.
Discussion
In this work, through a gene expression dataset
meta-analysis, we demonstrated that among DNA repair
systems, NER is the most upregulated in MM and it is
strongly associated with patients’ prognosis. On these
bases, for the first time, we decided to evaluate the activ-
ity of NER-targeting agent trabectedin in this setting.
Trabectedin has been granted approval for the treatment
of advanced soft tissue sarcoma and for relapsed ovarian
cancer, while several studies are ongoing to evaluate its
activity in other malignancies [28]. In our experimental
models, it exerts strong anti-myeloma activity on cell
lines and primary cells at nanomolar concentrations,
both in conventional 2D and in advanced 3D models.
Interestingly, a quick response to trabectedin was associ-
ated to a high expression of ERCC1 protein, thus con-
firming its already known role in trabectedin mechanism
of action [22, 23]. Additionally, trabectedin showed a
pleiotropic activity in MM, which includes DNA DSBs
generation, cell cycle arrest, exacerbation of cellular
stress, reduction of angiogenesis, and immunomodula-
tion (Fig. 5h). Regarding the latters, two different aspects
have been of our interest. Several studies showed that
trabectedin has significant effects on tumor microenvir-
onment by impairing tumor-associated macrophages
[32, 33]. Accordingly, in 3D Matrigel-spheroids, mono-
cytes promoted MM cells viability and proliferation,
which are strongly reduced by trabectedin. In the same
setting, trabectedin modulated the pro-inflammatory
cytokine/chemokine network by reducing MCP1,
VEGF-A, and IL-10 which functionally translated into a
decrease of pro-angiogenic potential. These effects are of
particular relevance taking into account the role of in-
flammation and angiogenesis in MM [12, 45]. A relevant
finding is, in our opinion, the triggering activity of
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trabectedin on the innate immune response against MM
by increased expression of NKG2D ligands MICA/B and
ULBP1. The relevance of NK response in MM pathogen-
esis has been deeply investigated [37, 46, 47], and in pa-
tients, a downregulation of surface expression of MICA
on malignant plasma cells or a decline in NK-dependent
immune-surveillance has been observed when MGUS
progresses to symptomatic MM [48, 49]. Furthermore,
the expression of killer cell inhibitory receptor (KIR) li-
gands, such as MHC class I, increases in advanced dis-
ease, impairing the balance between stimulatory and
inhibitory signaling to promotion of NK inactivation
[48]. Moreover, most of the anti-MM activity of
immune-modulatory agents (IMiDs) has been attributed
to their capability to induce proliferation and activation
of NK cells [50]. Along this line, our study provides
novel evidence that trabectedin-treated MM cells are
more recognizable by innate immune effectors and that
the drug strongly induces NK cell activation. These re-
sults are consistent with previous evidence reporting
that low doses of doxorubicin or melphalan are able to
increase NK activating receptors ligands with a mechan-
ism dependent on DNA damage response [8].
In our work, we further investigated the regulatory
network underlying trabectedin-mediated NKG2D li-
gands upregulation in MM. To this aim, the expression
levels of all known MICA/B regulatory factors were eval-
uated by GEP and validated at protein level. Our results
showed that trabectedin increased the expression level
of the MICA/B-positive regulator E2F1 and reduced the
expression of the negative regulators IRF4 and IKZF1.
These findings are in line with recent reports where the
phosphorylation of the kinases ATM/ATR, together with
the production of ROS, induced the activation of E2F1
that, in turn, could promote MICA, MICB, and PVR tran-
scription [51]. Additionally, the inhibition of IRF4 and
IKZF1/3 by several drugs such as bromodomain and extra
terminal domain inhibitors (BETi) and IMiDs has been
found to induce MICA and PVR transcription [7, 52].
The mechanism through which trabectedin could af-
fects E2F1, IRF4, and IKZF1 expression still remains elu-
sive. Several reports in this field suggest the existence of
possible networks between all these molecules that could
account for the fine and reciprocal regulation we ob-
served in this study [53–56]. Specifically, CUL4A, one of
the four components (together with DDB1, CRBN, and
DDB2) of a complex ubiquitination machinery respon-
sible for lenalidomide-induced IKZF1 and IKZF3 deg-
radation, has been demonstrated to be necessary for
trabectedin activity [56]. Additionally, we observed an
upregulation of three of the four genes of the ubiquitina-
tion machinery after trabectedin treatment. However,
the strong activation of caspase 3 quickly induced by tra-
bectedin treatment may account for the degradation of
IKZF1 [57], with a mechanism that is independent from
CRBN expression (differently from what observed with
IMiDs). Both mechanisms could than contribute to
IKZF1 downregulation that in turn inhibits IRF4 expres-
sion at transcriptional level [58], reducing the repressive
regulation on MICA/B promoter.
On the other side, E2F1 has been demonstrated to be
induced in response to several DNA-damaging agents,
including UV radiation and a number of chemothera-
peutic drugs [59]. This translates in an increase in
protein stability and in some cases apoptosis [59]. Fur-
thermore, taking into account that reprogramming the
immune response requires rapid changes at both tran-
scriptional and post-transcriptional level, we hypothe-
sized a role for miRNAs in finely tuning this regulatory
network. By using miRNA target prediction tools,
miR-17 family has been identified as the most relevant
in MM biology predicted to target at the same time
MICA, MICB, and E2F1. We then confirmed that tra-
bectedin downregulates miR-17 and miR-20a in MM
cells and that miR-17-92 stable overexpression produced
by a lentiviral construct reduces trabectedin-dependent
upregulation of NKG2D ligands, making MM cells re-
sistant to drug-induced apoptosis. The latter result ap-
pears to be in line with recent findings where miR-17-92
upregulation was found to be associated with resistance
to trabectedin [60]. Additionally, the downregulation of
miR-17 and miR-20a may further increase the upregu-
lation of E2F1 [10], contributing to cell cycle arrest,
and MICA/B surface expression. Thus, trabectedin
could induce E2F1 upregulation through both DNA
damage and miR-17 and miR-20a downregulation.
However, the mechanism by which trabectedin re-
duces miR-17-92 transcription and impairs the
miR-17-92/E2F1 auto-regulatory loop [61, 62] is cur-
rently under investigation.
Conclusion
Altogether, our results demonstrated a potent and
pleiotropic preclinical activity of trabectedin in mul-
tiple myeloma. Specifically, we here demonstrated an
overexpression of NER genes in malignant MM
plasma cells that strongly correlates with patients’
prognosis. Accordingly, we found that trabectedin ex-
erts cytotoxicity on both MM cell lines (including
drug-resistant derivatives) and primary MM patients
derived cells at nanomolar concentrations, by indu-
cing apoptosis, as confirmed by upregulation of cas-
pase3 and downregulation of BCL-2, and cell cycle
arrest increasing S-phase. Trabectedin also induces
ROS production, with activation of stress response
pathways, and DNA damage, enhancing the cytotoxic
effect on MM cells. Importantly, trabectedin over-
comes microenvironment-induced resistance, impairs
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MM-macrophages-mediated neo-angiogenesis, and in-
duces NKG2D ligands upregulation enhancing
NK-mediated killing. On the basis of these findings,
trabectedin emerges as a new potential agent for the
treatment of MM that deserves further translational
and clinical investigation.
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Additional file 1: Table S1. List of genes included in DNA repair
systems. (XLSX 11 kb)
Additional file 2: Figure S1. A Meta-analysis of 4 different GEP datasets
of MM comparing the expression levels of genes belonging to different
DNA-repair pathways (BER, MMR, HR, c-NHEJ, a-NHEJ, FA) in PCs from MM
patients with PCs from healthy donors. B For each panel: on the left, forest
plot showing the results of the multivariate COX regression analysis
performed on all genes included in the specific DNA repair system. On the
right, Kaplan-Meyer curve report results of prognostic system in which
patients were divided into “low” and “high” risk group, according to the
expression of genes identified by previous multivariate analysis. (PDF 605 kb)
Additional file 3: Figure S2. A Dot plots reporting pro-apoptotic
activity of trabectedin after 24 h treatment in primary myeloma cells from
three different patients. On the right, histogram reporting the % of viable
cells. B Western blot images of a panel of 12 MM cell lines representing
proteins belonging to NER pathway, which not exhibited a pattern
associated with response to trabectedin. C Expression of the genes
belonging to the NER pathway obtained by interrogating 2 different
publicly available datasets (GSE68379 and GSE6205) including several MM
cell lines used in our in vitro experiments. Cell lines segregate, in an
unsupervised hierarchical clustering, accordingly to their response to
trabectedin. D Dot plots of apoptotic activity of trabectedin in OPM2 and
MM1S in presence (right) or absence (left) of monocytes, treated with 1 nM
and 0.1 nM of the trabectedin, respectively in 3D model. E Unsupervised
hierarchical clustering demonstrating that both duplicates achieved
comparable results. In green cluster: trabectedin treated U266; in yellow
cluster: control U266. F Shows the first 9 results of the gene set enrichment
analysis according to their ranking. Importantly, 5/9 gene-sets affected
involves DNA damages. Additionally, GSEA correctly identified that the
whole transcriptome modulation may be dependent upon trabectedin
treatment. *: p < 0.05. (PDF 1280 kb)
Additional file 4: Figure S3. A GSEA results according to clueGO
grouped by functions dependent on upregulated or downregulated
genes. B Genes belonging to NER pathway resulted to be upregulated
following trabectedin treatment in U266. Below, western blot to confirm
DDB2 upregulation in 2 different cell lines. (PDF 974 kb)
Additional file 5: Figure S4. A Western blot showing expression levels
of anti-apoptotic proteins BCL-2 and MCL-1 in U266 and MM1S treated
with different doses of trabectedin. B Representative dot plot of
apoptosis induction and ROS production in U266 and MM1S cells after
trabectedin-treatment respect to control, in presence or absence of
ascorbic acid. C Western blot reporting protein expression of cell-cycle and
DNA-damage regulators (p21, p-Chk2, RAD51 and gH2AX) in OPM2 cell line,
after trabectedin treatment. D Representative immunohistochemistry
showing gamma-h2ax foci (in brown) in the nuclei of U266 cells growth in
matrigel-based spheroids, after 2.5 nM trabectedin treatment. E Surface
expression of MICA/B and ULBP1 in U266, OPM2, RPMI8226 and MM1S cells
treated with different concentrations of trabectedin for 48 h. All results
represent the mean of at least 3 different individual experiments. F Dot plots
report CD107a surface expression on NK-92 CI co-cultured with RPMI8226
untreated and exposed to trabectedin for 48 h. In the lowest part, histogram
reporting the mean of the CD107a expression on NK92 co-cultured with
U266 and OPM2 in 3 different experiments. G Gene expression levels of
CRBN, CUL4 and DDB2 genes, all involved in the ubiquitination of IKZF1
protein, extracted from our gene expression profiling performed on U266
after 24 exposure to trabectedin. H Expression of pri-miR-17-92 in U266 and
OPM2 in both cell lines after trabectedin treatment (2.5 Nm for U266 and 1
nM for OPM2). I Expression of miR-19b and miR-92a in U266 and OPM2
in absence or presence of trabectedin. These miRNAs do not belong to
miR-17 family and were used as control for trabectedin specific activity.
J Expression levels of mature miRNAs belonging to miR-17-92 cluster in
stably pri-miR-17-92 overexpressing U266. K Representative dot plot of
apoptotic activity of trabectedin treatment (2 .5nM) in 17–92-U266 cells
respect to EV-U266 cells. *: p < 0.05. (PDF 950 kb)
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